Stocks
Eli Lilly and CompanyLLY
NYSEHealthcarePharmaceuticals$985.08+0.80%
A major U.S. pharmaceutical manufacturer focused on developing and commercializing treatments for diabetes, obesity, oncology, immunology, and neuroscience. Its recent growth has been driven by blockbuster GLP-1 drugs for diabetes and weight loss, including Mounjaro and Zepbound, which have reshaped revenue expectations across the industry. Investors closely watch the company’s drug pipeline, clinical trial outcomes, and capacity expansion as demand for metabolic disease treatments accelerates.
Market Cap: $929.3B52W Range: $623.78 – $1133.95
Congressional Interest in Eli Lilly and Company (LLY)
16 members of Congress have disclosed 50 trades in Eli Lilly and Company (LLY), a Healthcare company. The buy/sell breakdown shows 32 purchases versus 18 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
16
Buys
32
Sells
18
Who in Congress Is Trading LLY?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-01-27 | Josh Gottheimer | sell | $1K – $15K |
| 2023-01-18 | Greg Landsman | buy | $1K – $15K |